On the path to controlling high blood pressure, tolerability matters as much as efficacy—and a sweeping analysis of 716 clinical trials now shows which medication combinations patients are most likely to stick with long term. The study, which examined data from 159,362 participants, found that blood pressure drugs containing an angiotensin II receptor blocker (ARB) had the lowest rates of treatment discontinuation due to side effects, with some ARB regimens performing better than placebo itself.
The stakes of this research are enormous. The World Health Organization's Global Hypertension Report found that 1.4 billion people were living with hypertension in 2024—yet only slightly more than one in five of those diagnosed have their condition under control. Fear of side effects remains a major barrier to effective treatment, discouraging patients from starting medication, accepting higher doses, or staying on therapy long term. Between 30 and 80 percent of people newly prescribed blood pressure medication stop taking it within the first year, often because of headaches, fatigue, swollen ankles, and other unwelcome effects.
Researchers used network meta-analysis to compare different treatments simultaneously, even when they had never been tested directly against each other in the same trial. They focused on discontinuation rates driven by side effects, while also tracking four complaints that frequently drive patients away: headaches, dizziness, swelling, and coughing. The analysis ranked treatments using SUCRA (Surface Under the Cumulative Ranking Curve), creating a tolerability leaderboard.
The winner was clear: an ARB paired with a calcium channel blocker (CCB) emerged as the best-tolerated combination. ARBs dominated the top rankings overall, appearing in four of the five best-tolerated treatment options. This is significant because ARBs work by blocking a hormone that narrows blood vessels, allowing them to relax and blood to flow more freely—and apparently, this mechanism comes with minimal side effects for most patients.
The picture was less favorable for other regimens. Calcium channel blockers alone proved substantially more difficult for patients to tolerate, leading to higher discontinuation rates. Combinations pairing beta-blockers with diuretics also saw elevated rates of patients stopping treatment due to adverse effects. Interestingly, most blood pressure medications except CCBs were associated with fewer headaches than placebo, though CCBs themselves can cause headaches, possibly through a mechanism called cerebral vasodilation.
The research fills a two-decade gap in comprehensive medication comparison. Until now, no study had systematically ranked how well people tolerate the three most common blood pressure drugs—ARBs, beta-blockers, and CCBs—or their various combinations. Each works through a different mechanism: beta-blockers slow heart rate and ease pressure on blood vessel walls, while CCBs prevent calcium from entering heart and blood vessel cells, helping vessels relax.
These findings matter because controlling hypertension is urgent work. Left unmanaged, high blood pressure quietly damages blood vessels and vital organs over time, making the heart work harder than normal. Yet medication only helps if patients actually take it. By identifying which drug combinations offer the gentlest side effect profiles, physicians can better match treatments to individual patients—turning tolerability from a barrier into a bridge toward long-term health.